Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.

Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.

The Report “EpiCast Report: Migraine – Epidemiology Forecast to 2023″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “EpiCast Report: Migraine – Epidemiology Forecast to 2023″ in subject line and your contact details to purchase this report or get your questions answered.
Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following symptoms: nausea; vomiting; and increased sensitivity to light, sound and smell (Bigal and Lipton, 2006). Because migraine is one of the most prevalent types of headache, there is a substantial economic and social burden associated with the condition worldwide, and it is therefore recognized as a high-priority public health problem by the World Health Organization (WHO) (Leonardi et al., 2005; Lusic, 2001). The Global Burden of Disease (GBD) study in 2010 ranks migraine as the first among the neurological disorders (Leonardi and Raggi, 2013).
Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=149041 .
In 2023, It epidemiologists forecast that the total prevalent cases of migraine in the 7MM remained almost the same, with 75.83 million total prevalent cases in 2013 and 76.38 million total prevalent cases, with an annual growth rate (AGR) of 0.07% in the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of migraine, with 29.61 million total prevalent cases in 2013 and 31.13 million total prevalent cases in 2023.
It epidemiologists obtained total prevalence data for migraine from peer-reviewed journals and population-based studies in the respective markets and used consistent methodology to ensure comparability of results. Furthermore, It epidemiologists made a meaningful assumption that the ageand sex-specific total prevalence of migraine in the 7MM would remain constant throughout the forecast period because epidemiologic literature suggests relatively stable trends in the prevalence of migraine worldwide, thereby providing a realistic and meaningful forecast for the ageand sex-specific total prevalent cases of migraine in the 7MM.
Complete report is available @ http://www.rnrmarketresearch.com/epicast-report-migraine-epidemiology-forecast-to-2023-market-report.html . Read more on “EpiCast Report: Migraine – Epidemiology Forecast to 2023” report below.